Cargando…

The use of sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists versus sulfonylureas and the risk of lower limb amputations: a nation-wide cohort study

BACKGROUND: Numerous studies have investigated the potential association of sodium-glucose co-transporter-2 inhibitors (SGLT2-Is) with an increased risk of lower limb amputations (LLAs), but have produced conflicting results. Particularly studies comparing SGLT2-Is to glucagon-like peptide-1 recepto...

Descripción completa

Detalles Bibliográficos
Autores principales:	Werkman, Nikki C. C., Driessen, Johanna H. M., Stehouwer, Coen D. A., Vestergaard, Peter, Schaper, Nicolaas C., van den Bergh, Joop P., Nielen, Johannes T. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10311702/ https://www.ncbi.nlm.nih.gov/pubmed/37386427 http://dx.doi.org/10.1186/s12933-023-01897-2

Ejemplares similares

Use of Glucagon-Like-Peptide 1 Receptor Agonists and Risk of Fracture as Compared to Use of Other Anti-hyperglycemic Drugs
por: Driessen, Johanna H. M., et al.
Publicado: (2015)

Thiazolidinediones and Glucagon‐Like Peptide‐1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study
por: van Dalem, Judith, et al.
Publicado: (2021)

The incidence of fractures at various sites in newly treated patients with type 2 diabetes mellitus
por: Sarodnik, Cindy, et al.
Publicado: (2022)

Relationship Between Nonalcoholic Fatty Liver Disease Susceptibility Genes and Coronary Artery Disease
por: Brouwers, Martijn C.G.J., et al.
Publicado: (2019)

Agonist-antagonist muscle strain in the residual limb preserves motor control and perception after amputation
por: Song, Hyungeun, et al.
Publicado: (2022)

Hypoglycemia Risk With SGLT2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists Versus Sulfonylureas Among Medicare Insured Adults With CKD in the United States
por: Zhao, Julie Z., et al.
Publicado: (2022)

Association of common gene variants in glucokinase regulatory protein with cardiorenal disease: A systematic review and meta-analysis
por: Simons, Pomme I. H. G., et al.
Publicado: (2018)

In-Utero Limb Amputation
por: Sharma, Vibha, et al.
Publicado: (2017)

Publisher Correction: Agonist-antagonist muscle strain in the residual limb preserves motor control and perception after amputation
por: Song, Hyungeun, et al.
Publicado: (2022)

Real‐world weight change among patients treated with glucagon‐like peptide‐1 receptor agonist, dipeptidyl peptidase‐4 inhibitor and sulfonylureas for type 2 diabetes and the influence of medication adherence
por: Carls, G. S., et al.
Publicado: (2017)

Meal-Related Increases in Microvascular Vasomotion Are Impaired in Obese Individuals: A potential mechanism in the pathogenesis of obesity-related insulin resistance
por: Jonk, Amy M., et al.
Publicado: (2011)

Prevalent Morphometrically Assessed Vertebral Fractures in Individuals With Type 2 Diabetes, Prediabetes and Normal Glucose Metabolism: The Maastricht Study
por: van Hulten, Veerle, et al.
Publicado: (2022)

Adulthood Socioeconomic Position and Type 2 Diabetes Mellitus—A Comparison of Education, Occupation, Income, and Material Deprivation: The Maastricht Study
por: Qi, Yuwei, et al.
Publicado: (2019)

Amputations with Special Reference to Phantom Limb Sensations
por: Stevenson, G. H.
Publicado: (1950)

Design, Synthesis, Molecular Modeling and Anti-Hyperglycemic Evaluation of Quinazoline-Sulfonylurea Hybrids as Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) and Sulfonylurea Receptor (SUR) Agonists
por: El-Zahabi, Mohamed Ayman, et al.
Publicado: (2022)

Complete Amputation of Two Limbs
Publicado: (1902)

Pattern of Limb Amputations in Liberia
por: Weyhee, Joseph K., et al.
Publicado: (2019)

Evidence‐based comparison of glucagon‐like peptide receptor agonists and sodium–glucose cotransporter 2 inhibitors
por: Watada, Hirotaka
Publicado: (2019)

Patients’ Preferences for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
por: Banjara, Bidur, et al.
Publicado: (2022)

Cycling in people with a lower limb amputation
por: Poonsiri, Jutamanee, et al.
Publicado: (2021)

The Association Between β-Blocker Use and Cardiorespiratory Fitness: The Maastricht Study
por: Nielen, Johannes T. H., et al.
Publicado: (2018)

The molecular pharmacology of glucagon agonists in diabetes and obesity
por: Novikoff, Aaron, et al.
Publicado: (2023)

Special Considerations for Multiple Limb Amputation
por: Pasquina, Paul F., et al.
Publicado: (2014)

Lower Limb Amputation Rates in Germany
por: Walter, Nike, et al.
Publicado: (2022)

Drug utilization in the Maastricht Study: A comparison with nationwide data
por: Nielen, Johannes T.H., et al.
Publicado: (2020)

Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM
por: McKee, Alexis, et al.
Publicado: (2020)

Amputation-specific and generic correlates of participation among Veterans with lower limb amputation
por: Erbes, Christopher R., et al.
Publicado: (2022)

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and risk of depression among older people with hypertension
por: van Sloten, Thomas T, et al.
Publicado: (2022)

Towards functional restoration for persons with limb amputation: A dual-stage implementation of regenerative agonist-antagonist myoneural interfaces
por: Srinivasan, Shriya S., et al.
Publicado: (2019)

Risk of contralateral lower limb amputation and death after initial lower limb amputation – a population-based study
por: Huseynova, K., et al.
Publicado: (2018)

Cycling of people with a lower limb amputation in Thailand
por: Poonsiri, Jutamanee, et al.
Publicado: (2019)

Reorganization of sensorimotor representations of the intact limb after upper but not lower limb traumatic amputation
por: Marneweck, Michelle, et al.
Publicado: (2023)

RETRACTED ARTICLE: Secular trends in major osteoporotic fractures among 50+ adults in Denmark between 1995 and 2010
por: Abtahi, Shahab, et al.
Publicado: (2018)

Secular trends in major osteoporotic fractures among 50+ adults in Denmark between 1995 and 2010
por: Abtahi, Shahab, et al.
Publicado: (2019)

Sulfonylureas: Asset or liability?
por: Lakhani, Om J., et al.
Publicado: (2015)

Sulfonylureas at the Glomerular Battlefield
por: Kalra, Sanjay, et al.
Publicado: (2018)

CORRIGENDUM FOR “Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM”
Publicado: (2020)

Erratum to: Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM
Publicado: (2021)

Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
por: Lin, Tzu-Yi, et al.
Publicado: (2023)

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
por: Saraiva, Francisco Kerr, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_julu0a6tiaqq8rrqs95truck47